Altered biodistribution of [68Ga]Ga-DOTA-TOC during somatostatin analogue treatment
European Journal of Nuclear Medicine and Molecular Imaging · 2024
DOI: 10.1007/s00259-024-06659-0 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, 2024. Verfasst von T van de Weijer und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology and Nuclear Medicine, ENETS Center of Excellence, Maastricht University Medical Center (MUMC+), P. Debeylaan 25, P.O. Box 580…. Hauptthemen laut MEDLINE: Neuroendocrine Tumors, Positron Emission Tomography Computed Tomography, Octreotide, Somatostatin. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universitätsklinikum RWTH Aachen.
Abstract (Originalsprache)
Purpose
The need for an interval between the administration of long-acting Somatostatin Receptor Analogues (SSA) and the [ 68 Ga]Ga-DOTA-TATE PET has been questioned based on recent literature in the new EANM guidelines. Here an earlier studies showed that SSA injection immediately before SSTR PET had minimal effect on normal organ and tumor uptake (1). However, data are scarce and there are (small) differences between [ 68 Ga]Ga-DOTA-TATE and [ 68 Ga]Ga-DOTA-TOC binding affinity, and it remains unknown whether these findings can be directly translated to scans with [ 68 Ga]Ga-DOTA-TOC as well. The purpose of this study was to assess the effect of SSA use on the biodistribution in a subsequent [ 68 Ga]Ga-DOTA-TOC PET/CT and compare this intra-individually across several cycles of SSA treatments.
Methods
Retrospectively, 35 patients with NENs were included. [ 68 Ga]Ga-DOTA-TOC PET at staging and after the 1st and 2nd cycle of SSA were included. SUVmean and SUVmax of blood, visceral organs, primary tumor and two metastases were determined. Also, the interval between SSA therapy and the PET scan was registered.
Results
Treatment with SSA resulted in a significantly higher bloodpool activity and lower visceral tracer uptake. This effect was maintained after a 2nd cycle of SSA therapy. Furthermore, there was an inverse relationship between bloodpool tracer availability and visceral tracer binding and a positive correlation between bloodpool tracer availability and primary tumor tracer uptake. With an interval of up to 5 days, there was a significantly higher bloodpool activity than at longer intervals.
Conclusion
Absolute comparison of the SUV on [ 68 Ga]Ga-DOTA-TOC PET should be done with caution as the altered biodistribution of the tracer after SSA treatment should be taken into account. We recommend not to perform a scan within the first 5 days after the injection of lanreotide.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiology and Nuclear Medicine, ENETS Center of Excellence, Maastricht University Medical Center (MUMC+), P. Debeylaan 25, P.O. Box 5800, 6202, 6229 HX, AZ, Maastricht, The Netherlands.
- School of Nutrition and Translational Research in Metabolism (NUTRIM), University of Maastricht (UM), P. Debeylaan 25, P.O. Box 5800, 6202, 6229 HX, AZ, Maastricht, The Netherlands.
- Department of Medical Oncology, ENETS Center of Excellence, MUMC+, P. Debeylaan 25, P.O. Box 5800, 6202, 6229 HX, AZ, Maastricht, The Netherlands.
- School for Oncology and Reproduction (GROW), UM, P. Debeylaan 25, P.O. Box 5800, 6202, 6229 HX, AZ, Maastricht, The Netherlands.
- School for Cardiovascular Diseases (CARIM), UM, P. Debeylaan 25, P.O. Box 5800, 6202, 6229 HX, AZ, Maastricht, The Netherlands.
- Department of Radiology and Nuclear Medicine, ENETS Center of Excellence, Maastricht University Medical Center (MUMC+), P. Debeylaan 25, P.O. Box 5800, 6202, 6229 HX, AZ, Maastricht, The Netherlands. fmottaghy@ukaachen.…
ORCID-Profile: T van de Weijer, J de Vos-Geelen, B Hermans, C Mitea, J A J van der Pol, T Lodewick, J E Wildberger, F M Mottaghy
Förderung
- Universitätsklinikum RWTH Aachen
Zitieren
APA
van de Weijer, T., Bemer, F., de Vos-Geelen, J., Hermans, B., Mitea, C., van der Pol, J. A. J., Lodewick, T., Wildberger, J. E., & Mottaghy, F. M. (2024). Altered biodistribution of [68Ga]Ga-DOTA-TOC during somatostatin analogue treatment. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-024-06659-0
Vancouver
van de Weijer T, Bemer F, de Vos-Geelen J, Hermans B, Mitea C, van der Pol JAJ, et al. Altered biodistribution of [68Ga]Ga-DOTA-TOC during somatostatin analogue treatment. European Journal of Nuclear Medicine and Molecular Imaging. 2024. doi:10.1007/s00259-024-06659-0
BibTeX
@article{vandeWeijer2024,
author = {van de Weijer, T and Bemer, F and de Vos-Geelen, J and Hermans, B and Mitea, C and van der Pol, J A J and Lodewick, T and Wildberger, J E and Mottaghy, F M},
title = {Altered biodistribution of [68Ga]Ga-DOTA-TOC during somatostatin analogue treatment},
journal = {European Journal of Nuclear Medicine and Molecular Imaging},
year = {2024},
doi = {10.1007/s00259-024-06659-0}
}
EUVIMED